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INTRODUCTION
The frequency of post-mastectomy breast reconstruction is in-
creasing, due to its benefits for body image, self-esteem, and 
quality of life. In the United States, breast reconstruction is the 
fifth most common reconstructive procedure performed by 
plastic surgeons [1]. Of the various breast reconstruction op-
tions, implant-based reconstruction is a relatively simple tech-
nique and has a shorter operative time than reconstruction with 
autologous tissue. Implant based reconstruction also has several 
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other advantages, including the absence of donor-site morbidity, 
rapid patient recovery, and a shorter hospital stay [2].
The use of acellular dermal matrix (ADM) has been estab-
lished as beneficial for prosthetic breast reconstruction. ADM 
provides support to mastectomy skin flaps, and minimizes fibro-
sis and the inflammatory response associated with the implant, 
thereby reducing capsular contracture [3].
Given these benefits, the use of implant-based breast recon-
struction has increased in recent years. However, the incidence 
of implant infection following breast reconstruction after mas-
tectomy has been reported to range from 2.5% to 24% [4]. In 
particular, infection requiring explantation remains the most 
devastating complication associated with implant-based breast 
reconstruction. Many treatment algorithms are available for pre-
venting reconstructive failure and infection. We reviewed the 
rates of infection (defined as cellulitis) and implant removal at 
our institution. Characterizing the clinical differences between 
the patients who experienced cellulitis and those who under-
went implant removal will provide knowledge that may be use-
ful for improving the salvage rate after infection.
The use of implants is linked to an increased risk of infection. 
Many surgeons have described the risk factors for infection in 
patients undergoing implant-based breast reconstruction. How-
ever, few studies have compared the occurrence of cellulitis and 
the need for implant removal. Therefore, the purpose of this in-
vestigation was to review cases of postoperative implant infec-
tion and to identify the risk factors for failure to salvage the 
breast device.
METHODS
Methods
From January 2010 to December 2016, 5 plastic surgeons at our 
institution performed 1,163 cases of implant-based reconstruc-
tion in 771 patients after total mastectomy for breast cancer. We 
retrospectively reviewed the records of these patients.
The type of mastectomy and reconstruction performed by the 
surgical oncologist or plastic surgeon varied within our popula-
tion. The mastectomy procedure was either a simple mastecto-
my or a modified radical mastectomy, depending on the results 
of the sentinel lymph node biopsy. All implants and expanders 
were placed in the subpectoralis muscle or using ADM as a 
sling. Interrupted 2-0 Vicryl sutures were used to affix the ADM, 
moving from the inframammary fold along the inferior breast. 
Drain insertion was defined as the placement of 1 or 2 drains 
per expander/implant. Drains were removed according to the 
amount and color of drainage.
Once every 2 weeks, in-office expansion was performed in tis-
sue expander patients. Percutaneous injections of 50–100 mL of 
saline at a time were performed. The timing of expansion could 
be delayed depending on patients’ postoperative treatment, 
such as chemotherapy or radiotherapy.
We defined cellulitis based on the criteria published by the 
Centers for Disease Control and Prevention, previously used by 
Ranganathan et al. [5], as follows: (i) a positive aseptically ob-
tained culture, (ii) symptoms including whole breast erythema 
and swelling, or (iii) a negative aseptically obtained culture but 
a physician’s diagnosis of infection for which antibiotics were 
prescribed [6]. Total reconstructive failure was defined as the 
requirement for complete explantation of the breast prosthesis.
For each patient, information about demographics and post-
operative complications, including infection, was collected and 
analyzed. Demographic factors, including the patient’s age, body 
mass index, history of chemotherapy, exposure to radiotherapy, 
and active smoking status, were assessed as possible risk factors 
for postoperative infection. In addition, the clinical features of 
patients who underwent explantation due to postoperative in-
fection were analyzed. Clinical data were also investigated, in-
cluding the presence and onset of infection symptoms and 
pathogens observed in cultures obtained from collected fluid or 
dehiscent wounds. Other postoperative complications, includ-
ing seroma, hematoma, and mastectomy skin necrosis, were re-
viewed. Finally, mastectomy type and the use of ADM were also 
analyzed.
The chi-square and Fisher exact tests were used to evaluate 
categorical data, while the 2-sample t-test was used to evaluate 
continuous variables. We reported adjusted odds ratios (ORs), 
95% confidence intervals, and corresponding P-values based on 
the model. All statistical analyses were performed with SAS ver. 
9.4 (SAS Institute, Inc., Cary, NC, USA), and statistical signifi-
cance was set at P < 0.05.
Management
Implant-related infections were suspected in patients who expe-
rienced pain and erythema at the site of implantation in the 
presence of fever. Occasionally, ultrasonography was performed 
to visualize the periprosthetic fluid in order to identify the ex-
tent and location of the infection and its relationship with the 
implant. In patients with a large fluid collection, ultrasound-
guided drainage was performed.
In patients suspected to have an implant-based infection, we 
carried out bacterial cultures from the surgical site or drained 
fluid, as well as blood tests, to identify the systemic infectious 
condition. Before culturing and checking for susceptibility to 
antibiotics, empiric broad-spectrum antibiotic therapy (400 mg 
of intravenous teicoplanin) was started. After the pathogen was 
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identified, and its susceptibility to antibiotics was confirmed, 
the target therapy was started to eradicate the infection. If the 
patient’s condition worsened or did not improve with adequate 
antibiotic therapy, we considered removing the implant. Pa-
tients with a systemic infection and poor general condition usu-
ally required immediate implant removal.
During the operation for implant removal, capsulectomy and 
debridement of the infected tissue were performed. The re-
moved implant and tissue were analyzed for the presence of aer-
obic bacteria, anaerobic bacteria, fungi, and nontuberculous 
mycobacteria.
After implant removal, systemic antibiotics were administered 
for about 14 days, followed by oral antibiotics for 7 days. Re-im-
plantation was recommended to patients 6–12 months later.
RESULTS
Patient characteristics
From January 2010 through December 2016, implants were 
placed in 771 patients for reconstruction after total mastectomy. 
The total number of reconstructions was 1,163, and the number 
of treated breasts was 832.
The characteristics of the patients who experienced a postoper-
ative implant infection are shown in Table 1. The infection rate 
was 4.99% (58 of 1,163 reconstructions). The median patient 
age was 45.6 years (range, 29–69 years), the median body mass 
index was 22.4 kg/m2 (range, 18.2–29.1 kg/m2), and the median 
follow-up period was 46 months (range, 16–65 months).
The demographic characteristics of the patients who had cel-
lulitis and underwent explantation are shown in Tables 2 and 3. 
The total salvage rate was 58.6% (34 of the 58 cases of infection) 
(Table 4). There was a significant difference in the time to 
closed suction drain removal (postoperative days) between the 
cellulitis group and the implant removal group. A longer time 
went by before the closed suction drain was removed in the im-
plant removal group; this may have been related to seroma, 
which was the most common complication of implant infection. 
Characteristics Infections (%) Total cases
Total number 58 (4.99) 1,163
   Direct to implant 26 (11.4) 229
   Tissue expander 32 (3.43) 934
Median age (yr) 45.6 (29–69) 45.2 (18–83)
Body mass index (kg/m2) 22.4 (18.2–29.1) 23.4 (15.9–49.4)
Table 1. Characteristics of the patients
No. Age(yr) Smoking HTN DM
Neoadjuvant 
CTx
Adjuvant 
CTx Postop RTx
Type of 
mastectomy
Axillary node 
dissection ADM use
  1 43 No No No No Yes No TM SLNB No
  2 33 No No No No Yes No TM SLNB No
  3 57 No Yes Yes No No No TM SLNB No
  4 39 No Yes No No No No TM ALND No
  5 40 No No No No No No TM SLNB No
  6 33 No No No No Yes Yes TM ALND No
  7 37 No No No No No No TM ALND No
  8 45 Yes No No No Yes No TM ALND No
  9 53 No No No No No No TM ALND Yes
10 45 No Yes No Yes No Yes TM ALND Yes
11 58 No Yes No No No No TM SLNB No
12 47 No No No No Yes Yes TM ALND Yes
13 47 No No No No Yes Yes TM ALND Yes
14 51 No No No No No No SSM SLNB Yes
15 45 No No No No Yes No SSM SLNB Yes
16 38 No No No No No Yes SSM SLNB Yes
17 45 No No No No No No NSM SLNB Yes
18 50 No No No No Yes No SSM ALND Yes
19 45 Yes No No No Yes No NSM ALND Yes
20 50 No No No No Yes Yes NSM ALND Yes
21 51 No No No No Yes No SSM SLNB Yes
22 62 No No No Yes Yes Yes NSM ALND Yes
23 46 No No No No No No TM SLNB Yes
24 54 No No No No Yes No SSM ALND Yes
HTN, hypertension; DM, diabetes mellitus; CTx, chemotherapy; Postop, postoperative;  RTx, radiotherapy; ADM, acellular dermal matrix; TM, total mastectomy; SLNB, sentinel 
lymph node biopsy; ALND, axillary lymph node dissection; SSM, skin-sparing mastectomy; NSM, nipple-sparing mastectomy.
Table 2. Details of cases of explantation
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Explantation after breast implant infection was performed more 
frequently in patients who underwent 2-stage expander/im-
plant reconstruction than in those who underwent direct-to-im-
plant reconstruction. A univariate logistic regression analysis 
found that 2-stage breast reconstruction was associated with 5.5 
times higher odds of explantation after breast implant infection 
than 1-stage breast reconstruction (Table 5).
Bacterial culture pathogens
The microorganism most frequently observed in our study was 
Staphylococcus aureus, with methicillin resistance observed in 
21.4% of the cases of infection. Acinetobacter baumannii was 
found in 14.3% of patients, and Staphylococcus epidermidis was 
reported in 8.93%. Of note, no bacterial growth was observed in 
25.0% of patients with a postoperative infection (Table 6).
A binary logistic regression analysis identified 2 bacterial infec-
tions that were predictors of implant removal: methicillin-resis-
tant S. aureus (MRSA) (OR = 15.743; 95% CI, 2.398–103.357) 
and A. baumannii (OR = 9.114; 95% confidence interval [CI], 
1.254–66.25) (Table 7).
Related wound complications
Other wound complications occurred, including seroma, 
wound dehiscence, skin flap necrosis, capsular contracture, and 
hematoma (Table 8). Seroma was noted in 23 of 58 patients. 
Skin flap necrosis was noted in 5 patients and hematoma oc-
curred in five patients. Five patients with skin flap necrosis un-
derwent revision surgery. Capsular contracture was noted in 2 
patients, both of whom underwent capsulectomy during ex-
plantation.
No. Age (yr) Smoking HTN DM
Neoadjuvant 
CTx
Adjuvant 
CTx
Adjuvant 
RTx
Type of 
mastectomy
Axillary node 
dissection ADM use
  1 35 No No No No No No TM SLNB No
  2 69 No Yes No No No No NSM SLNB No
  3 51 No No No No No No NSM ALND No
  4 49 No No No No No No TM ALND No
  5 33 No No No No Yes Yes TM SLNB No
  6 46 No Yes Yes No Yes No TM ALND No
  7 49 No Yes No No No No TM SLNB No
  8 42 No No No No Yes No TM ALND Yes
  9 52 No No No No No No TM SLNB Yes
10 37 No No No Yes No Yes TM ALND Yes
11 60 No No Yes No Yes Yes TM ALND No
12 32 No No No Yes No Yes TM ALND No
13 62 No No No No No No SSM SLNB Yes
14 43 No No No Yes No No TM SLNB Yes
15 35 No No No No No No NSM SLNB Yes
16 38 No No No No Yes Yes NSM ALND Yes
17 58 No No No No Yes No TM ALND Yes
18 45 No No No No No No NSM ALND Yes
19 29 No No No Yes No Yes NSM SLNB Yes
20 29 No No No Yes No Yes NSM ALND Yes
21 38 No No No No Yes No NSM ALND Yes
22 29 No No No Yes No Yes NSM ALND Yes
23 41 No No No No No No NSM SLNB Yes
24 53 No Yes No No Yes No NSM SLNB Yes
25 56 No No No No Yes No NSM ALND Yes
26 52 Yes No Yes No Yes No SSM SLNB Yes
27 48 No No No No Yes No NSM ALND Yes
28 35 No No No No No No NSM SLNB Yes
29 55 No No No No Yes No NSM SLNB Yes
30 44 No Yes No No No No NSM SLNB Yes
31 44 No No No No No No SSM SLNB Yes
32 47 No No No Yes No Yes NSM ALND Yes
33 42 No No No No No No NSM SLNB Yes
34 50 No No No No No No NSM SLNB Yes
HTN, hypertension; DM, diabetes mellitus; CTx, chemotherapy; RTx, radiotherapy; ADM, acellular dermal matrix; TM, total mastectomy; SLNB, sentinel lymph node biopsy; 
NSM, nipple-sparing mastectomy; ALND, axillary lymph node dissection; SSM, skin-sparing mastectomy.
Table 3. Details of cases of cellulitis
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DISCUSSION
This retrospective investigation included a large series of im-
plant-based reconstructions (n = 1,163) performed at a single 
medical center from January 2010 to December 2016.
Infectious complications of implant-based breast reconstruc-
tions are a significant cause of morbidity. Infectious complica-
tions may result in hospital readmission, delayed chemotherapy 
and/or radiation therapy, and explantation. Our definition of 
cellulitis related to implant infection was based on the Centers 
for Disease Control and Prevention criteria, previously used by 
Ranganathan et al. [5]
In other studies, the definition of infection was either unclear 
or broader than the definition used in the present study (i.e., in-
cluding patients treated with oral antibiotics at an outpatient 
clinic) [4,7]. Pinsolle et al. [7] reported an implant-associated 
infection rate of 13%. In our study, the total infection rate for 
implant-based breast reconstructions was 4.99%, and the sal-
vage rate was 58.6%. Once infection is detected, appropriate ini-
tial antibiotic therapy should be started as soon as possible. The 
58.6% salvage rate with antibiotic therapy observed in this study 
is very acceptable, and argues against early implant removal 
[8,9]. However in a statistical comparison of cases identified as 
having MRSA, A. baumannii, and no culture growth, the OR for 
explantation in the MRSA and A. baumannii groups was mean-
ingfully high. This observation suggests that implant removal 
can be considered when clinical signs worsen and/or when 
MRSA or A. baumannii is identified. Spear and Seruya [10] re-
ported a high risk of reconstruction failure in infections caused 
by Gram-negative bacteria or MRSA. According to other stud-
ies, the most common cause of breast infection was coagulase-
negative Staphylococcus (CNS) [11]. CNS is known to be part 
of the endogenous flora and is associated with the periareolar 
approach. In our study, most of the implant-related infections 
were caused by MRSA, which might reflect the severity of infec-
Characteristic Cellulitis Implant removal P-value
Total number 34 (58.6) 24 (41.4) -
   Direct to implant 22 (78.6) 6 (21.4) 0.0029
   Tissue expander 12 (40.0) 18 (60.0)
Median age (yr) 44.9 (34–69) 46.4 (18–83) 0.5451
Body mass index (kg/m2) 22.0 (19.2–29.1) 21.4 (18.2–25.9) 0.4027
Onset time of infection 20 (5–150) 16.5 (3–191) 0.3201
Neoadjuvant CTx 7 (20.59) 2 (8.33) 0.2816
Adjuvant CTx 12 (35.29) 13 (54.17) 0.1529
Adjuvant RTx 9 (26.47) 7 (29.17) 0.8210
HTN 5 (14.71) 4 (16.67) 0.9999
DM 3 (8.82) 1 (4.17) 0.6351
Smoking Hx 1 (2.94) 2 (8.33) 0.5637
ADM use 25 (73.53) 15 (62.5) 0.3712
Axillary node dissection 16 (47.06) 13 (54.17) 0.5939
HV removal date #1 (POD) 11 (3–40) 18 (5–38) 0.0433
HV removal date #2 (POD) 16.5 (3–52) 20 (5–29) 0.8642
Values are presented as median (range) or number (%).
CTx, chemotherapy; RTx, radiotherapy; HTN, hypertension; DM, diabetes mellitus; 
Hx, history; ADM, acellular dermal matrix; HV, Hemovac; POD, postoperative day.
Table 4. Procedural and clinical characteristics of patients 
who experienced cellulitis or reconstruction failure
Variable Odds ratio (95% confidence interval) P-value
MRSA vs. no growth 15.743 (2.398, 103.357) 0.0041
CNS vs. no growth 8.12 (0.853, 77.257) 0.0684
Pseudomonas aeruginosa vs. no growth 9.671 (0.639, 146.263) 0.1016
Acinetobacter baumannii vs. no growth 9.114 (1.254, 66.25) 0.0290
Other pathogen vs. no growth 1.765 (0.276, 11.304) 0.5486
MRSA, methicillin-resistant Staphylococcus aureus; CNS, coagulase-negative 
Staphylococcus.
Table 7. Univariate logistic regression for implant removal
Wound complication No. Cellulitis (%) Explantation
Seroma 23 15 (65.2) 8 (34.8)
Wound dehiscence and skin flap necrosis 5 3 (60) 2 (40)
Hematoma 5 0 5 (100)
Capsular contracture (at least grade III) 2 0 2 (100)
No other complication 31 19 (57.6) 14 (42.4)
Table 8. Wound complications in patients with a 
postoperative implant infection
Variable Odds ratio (95% confidence interval) P-value
Two-stage expander/
implant reconstruction
5.5 (1.722, 17.566) 0.004
Table 5. Univariate logistic regression for implant removal
Bacterial culture No. (%) Cellulitis Explantation
Gram-positive 
Methicillin-resistant 
Staphylococcus aureus
12 (21.4) 3 (9.38) 9 (37.5)
Methicillin-sensitive 
Staphylococcus aureus
7 (12.5) 6 (18.75) 1 (4.17)
Staphylococcus epidermidis 5 (8.93) 2 (6.25) 3 (12.5)
Methicillin-resistant 
Staphylococcus epidermidis
4 (7.14) 3 (9.38) 1 (4.17)
Other 3 (5.36) 2 (6.25) 1 (4.17)
Gram-negative
   Acinetobacter baumannii 8 (14.3) 3 (9.38) 5 (20.83)
   Pseudomonas aeruginosa 3 (5.36) 1 (3.13) 2 (8.33)
No growth 14 (25.0) 12 (37.5) 2 (8.33)
Table 6. Pathogens in bacterial cultures
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tions requiring explantation. MRSA is becoming increasingly 
more prominent, not only as a pathogen causing nosocomial in-
fections, but also as a community-acquired pathogen causing se-
vere skin and soft tissue infections. To prevent CNS, it is impor-
tant to minimize skin contamination. Nipple shields may be 
helpful as well.
At our institution, explantation after breast implant infection 
was performed more frequently in patients who underwent 
2-stage expander/implant reconstruction than in those who un-
derwent direct-to-implant reconstruction. This may have been 
because of a higher risk of developing an ascending infection 
from endogenous skin flora and traumatic events during the ex-
pander inflation procedure. The need for a second operation for 
the implant expander may also increase the risk of infection.
Interestingly, our study showed a 25.0% rate of negative cul-
tures of samples obtained from aspirated fluid or the surface of 
deep wounds. This finding might have resulted from prior anti-
biotic treatment if a patient was treated at the first sign or symp-
tom of postoperative infection. In these cases, the use of appro-
priate antibiotics for management is difficult, and infection con-
trol can be delayed. However, our results indicated that when no 
pathogen was detected, the breast device could be salvaged with 
a high probability of success (Table 6).
In the present study, seroma formation was observed in 50% 
of patients who underwent explantation. In addition, complica-
tions related to seroma occurred in 23 cases (Table 8). Several 
methods are available to help prevent seroma formation. Quilt-
ing sutures and the intraoperative inflation of tissue expanders 
with injectable saline are used to reduce dead space. Additional-
ly, restricted exercise and elevation of the arm ipsilateral to the 
affected breast can help minimize seroma formation.
After mastectomy for the management of breast cancer, the 
breast parenchyma is removed, which can result in relative isch-
emia of the skin flaps due to disruption of the blood supply. For 
these reasons, the ADM might not function as expected. Addi-
tionally, pressure from the implants and the thinner mastectomy 
skin flap are associated with wound complications, such as 
wound dehiscence, skin flap necrosis, and seroma formation. In 
such cases, wound healing can be delayed, and infection is more 
likely to occur.
This study has some limitations. First, the definition of im-
plant infection was restricted to cellulitis and implant explanta-
tion. Our reported infection rate seems to be underestimated. 
Subclinical infection or red breast syndrome were not analyzed 
in this study. Second, 5 plastic surgeons who used different tech-
niques for implant-based breast reconstruction performed the 
reconstructions. Variations in implant irrigation, pocket irriga-
tion, draping and glove changes, and other specific sterility tech-
niques may have contributed to the infection rates and poten-
tially altered the results. However, our large volume of cases may 
offset this limitation. Third, this study is limited by its retrospec-
tive nature. Fourth, we were not able to identify microorganisms 
in all cases of infection. In 2 cellulitis cases, we were not able to 
perform a bacteria culture. Lastly, the range of the 95% CIs for 
the risk of explantation after breast implant infection was large, 
due to the relatively small sample size.
The high salvage rate found in this study argues against early 
implant removal [8,9]. However, if a breast implant infection is 
associated with MRSA or A. baumannii and if the patient’s clini-
cal symptoms do not improve, surgeons should consider im-
plant removal. Finally, seroma collection was the most common 
infection-related complication, and leading to drain prolonga-
tion and increasing the explantation rate. The results of this 
study will improve our understanding of the risk factors for in-
fection and may help prevent infections in clinical practice.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
REFERENCES
1. Weichman KE, Levine SM, Wilson SC, et al. Antibiotic se-
lection for the treatment of infectious complications of im-
plant-based breast reconstruction. Ann Plast Surg 2013;71: 
140-3.
2. Cordeiro PG, McCarthy CM. A single surgeon’s 12-year ex-
perience with tissue expander/implant breast reconstruc-
tion: part I. A prospective analysis of early complications. 
Plast Reconstr Surg 2006;118:825-31.
3. Nahabedian MY. Acellular dermal matrices in primary 
breast reconstruction: principles, concepts, and indications. 
Plast Reconstr Surg 2012;130(5 Suppl 2):44S-53S.
4. Francis SH, Ruberg RL, Stevenson KB, et al. Independent 
risk factors for infection in tissue expander breast recon-
struction. Plast Reconstr Surg 2009;124:1790-6.
5. Ranganathan K, Santosa KB, Lyons DA, et al. Use of acellu-
lar dermal matrix in postmastectomy breast reconstruction: 
are all acellular dermal matrices created equal? Plast Recon-
str Surg 2015;136:647-53.
6. Pittman TA, Fan KL, Knapp A, et al. Comparison of differ-
ent acellular dermal matrices in breast reconstruction: the 
50/50 study. Plast Reconstr Surg 2017;139:521-8.
7. Pinsolle V, Grinfeder C, Mathoulin-Pelissier S, et al. Com-
plications analysis of 266 immediate breast reconstructions. 
Song JH et al. Infection in breast implants
522
J Plast Reconstr Aesthet Surg 2006;59:1017-24.
8. Snyderman RK. Breast augmentation. In: Snyderman RK, 
editor. Symposium on Neoplastic and Reconstructive Prob-
lems of the Female Breast. St Louis: Mosby; 1973.  p.32-7.
9. Southwick HW, Economou SG, Otten JW. Prosthetic re-
placement of chest-wall defects; an experimental and clini-
cal study. AMA Arch Surg 1956;72:901-7.
10. Spear SL, Seruya M. Management of the infected or exposed 
breast prosthesis: a single surgeon’s 15-year experience with 
69 patients. Plast Reconstr Surg 2010;125:1074-84.
11. Nahabedian MY, Tsangaris T, Momen B, et al. Infectious 
complications following breast reconstruction with expand-
ers and implants. Plast Reconstr Surg 2003;112:467-76.
